Asset profile
Pumitamig
Multispecific antibody
Phase 3underway
Evidence outlook · registrational
Non-Small Cell Lung Cancer: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2029-01.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 58 further along in development.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Pumitamig: this drug | Phase 3 | Multispecific antibody | PD-L1 and VEGF-A | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 | ||
| Brigatinib | Approved | Small molecule | ALK | ||
| Capmatinib | Approved | Small molecule | MET | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Ceritinib | Approved | Small molecule | ALK | ||
| Crizotinib | Approved | Small molecule | ALK, ROS1, MET/HGFR, and RON |
…and 45 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(36 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
October 2026 (1)
Phase 1/2TNBCActive not recruiting
Est. primary completion 2026-10-30 · NCT05918133 · CT.gov ↗
What to watch
2027 (8)
January 2027 (2)
May 2027 (1)
Phase 2CRC (Colorectal Cancer)Recruiting
Est. primary completion 2027-05 · NCT07133750 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Extensive-stage Small-cell Lung Cancer, Small-cell Lung CancerActive not recruiting
Est. primary completion 2027-06 · NCT06449209 · CT.gov ↗
What to watch
July 2027 (1)
Phase 3Triple Negative Breast Cancer(TNBC)Active not recruiting
Est. primary completion 2027-07 · NCT06419621 · CT.gov ↗
What to watch
August 2027 (1)
Phase 1/2Advanced Solid TumorActive not recruiting
Est. primary completion 2027-08-13 · NCT05438329 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2027-11 · NCT07147348 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)Recruiting
Est. primary completion 2027-12 · NCT07255404 · CT.gov ↗
What to watch
2028 (10)
January 2028 (1)
Phase 2Recurrent GlioblastomaRecruiting
Est. primary completion 2028-01 · NCT07297212 · CT.gov ↗
What to watch
March 2028 (1)
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2028-03 · NCT07070232 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1/2Solid TumoursRecruiting
Est. primary completion 2028-07-31 · NCT07160725 · CT.gov ↗
What to watch
August 2028 (2)
Phase 2Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast CancersActive not recruiting
Est. primary completion 2028-08 · NCT06449222 · CT.gov ↗
What to watch
Phase 2Solid TumorsRecruiting
Est. primary completion 2028-08-15 · NCT07492680 · CT.gov ↗
What to watch
September 2028 (2)
October 2028 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-10 · NCT06841055 · CT.gov ↗
What to watch
November 2028 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-11 · NCT07111520 · CT.gov ↗
What to watch
December 2028 (1)
Phase 3Extensive-stage Small-cell Lung CancerRecruiting
Est. primary completion 2028-12 · NCT06712355 · CT.gov ↗
What to watch
2029 (7)
January 2029 (1)
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-01 · NCT06712316 · CT.gov ↗
What to watch
April 2029 (1)
Phase 1/2Relapsed/Refractory Small Cell Lung CancerRecruiting
Est. primary completion 2029-04-23 · NCT07325136 · CT.gov ↗
What to watch
August 2029 (2)
October 2029 (1)
Phase 1/2Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2029-10-15 · NCT07291076 · CT.gov ↗
What to watch
November 2029 (1)
Phase 1/2Advanced Renal Cell Carcinoma (RCC)Recruiting
Est. primary completion 2029-11-28 · NCT07293351 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3Breast NeoplasmsRecruiting
Est. primary completion 2029-12 · NCT07173751 · CT.gov ↗
What to watch
2030 (6)
February 2030 (1)
Phase 2/3Untreated, Unresectable, or Metastatic Colorectal CancerRecruiting
Est. primary completion 2030-02-02 · NCT07221357 · CT.gov ↗
What to watch
May 2030 (1)
Phase 1Renal Cell CarcinomaRecruiting
Est. primary completion 2030-05-03 · NCT07195682 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2Solid TumorsRecruiting
Est. primary completion 2030-06-30 · NCT06953089 · CT.gov ↗
What to watch
September 2030 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-09-18 · NCT07361497 · CT.gov ↗
What to watch
November 2030 (1)
Phase 2/3Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaRecruiting
Est. primary completion 2030-11-08 · NCT07221149 · CT.gov ↗
What to watch
December 2030 (1)
Phase 1/2Metastatic Colorectal CancerRecruiting
Est. primary completion 2030-12 · NCT07079631 · CT.gov ↗
What to watch
2031 (4)
February 2031 (1)
Phase 1/2Lung Cancer, Breast CancerRecruiting
Est. primary completion 2031-02-26 · NCT06618287 · CT.gov ↗
What to watch
August 2031 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2031-08-31 · NCT04895709 · CT.gov ↗
What to watch
October 2031 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2031-10-14 · NCT07361510 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-12-01 · NCT06837948 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.